Member Directory
Switzerland is one of the strongest biotech / pharma countries in Europe with global pharma, mature biotech and innovative start-ups, supported by world class research. The Embassy of Switzerland facilitates contacts to Swiss clusters for anyone interested in business or research partnerships.
Emberion develops and produces graphene photonics and electronics that will revolutionise infrared photodetectors and thermal sensors in applications ranging from hyperspectral and thermal imaging to night vision and X-ray detection.
The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training (www.ebi.ac.uk/industry).
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
Immunotherapeutics company targeting a new class of tumour specific antigens
Essen BioScience is a world leader in the field of innovative cell-based assays, reagents, instrumentation and custom services for discovery research. Our specialities include phenotypic 'live content' kinetic imaging assays based around IncuCyte Zoom (e.g. angiogenesis, neurite outgrowth, cell migration/invasion, apoptosis etc.) and high throughput automated electrophysiology for ion channel drug discovery and safety (e.g. hERG assays). Our live content imaging solution has been adopted by laboratories across all 10 of the world’s top pharmaceutical companies as well as more than 150 leading biotechnology and academic research institutions.
Selcia Ltd headquartered in Ongar, Essex, UK, is a leading worldwide provider of contract research services. Selcia Discovery provides integrated small molecule drug discovery, including general medicinal chemistry and biology capabilities, applicable across all target classes with a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products; (2) capillary electrophoresis-based fragment and natural product screening; and (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Selcia Radiolabelling specialises in GMP radiolabelled API and in 14C custom radiolabelling for metabolism, distribution and environmental fate studies.
A new synthetic biology start up
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of- the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Medimmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and preclinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.